argenex SE $ARGX Holdings Lifted by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC raised its position in argenex SE (NASDAQ:ARGX) by 14.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 211,330 shares of the company’s stock after purchasing an additional 26,343 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.34% of argenex worth $162,160,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in ARGX. Goldman Sachs Group Inc. boosted its position in argenex by 14.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 168,765 shares of the company’s stock worth $99,886,000 after acquiring an additional 21,805 shares during the period. Amundi raised its stake in shares of argenex by 8.1% during the first quarter. Amundi now owns 6,351 shares of the company’s stock valued at $3,747,000 after purchasing an additional 478 shares in the last quarter. Voya Investment Management LLC raised its stake in shares of argenex by 5.2% during the first quarter. Voya Investment Management LLC now owns 14,905 shares of the company’s stock valued at $8,822,000 after purchasing an additional 735 shares in the last quarter. Royal Bank of Canada lifted its holdings in argenex by 0.9% in the first quarter. Royal Bank of Canada now owns 38,306 shares of the company’s stock worth $22,673,000 after purchasing an additional 353 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in argenex by 40.5% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,611 shares of the company’s stock valued at $2,542,000 after buying an additional 1,328 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ARGX has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft lowered shares of argenex from a “buy” rating to a “hold” rating in a research note on Thursday, September 11th. Wells Fargo & Company upped their target price on argenex from $1,095.00 to $1,316.00 and gave the stock an “overweight” rating in a research report on Thursday, December 11th. Citigroup increased their price target on argenex from $1,041.00 to $1,124.00 and gave the company a “buy” rating in a research note on Monday, November 17th. Weiss Ratings reissued a “hold (c)” rating on shares of argenex in a research note on Wednesday, October 8th. Finally, Bank of America upped their price objective on argenex from $880.00 to $887.00 and gave the company a “buy” rating in a report on Tuesday, September 2nd. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $982.33.

argenex Stock Performance

NASDAQ:ARGX opened at $837.90 on Wednesday. The company has a market capitalization of $51.59 billion, a P/E ratio of 35.98, a P/E/G ratio of 0.87 and a beta of 0.36. The stock’s 50 day moving average price is $871.38 and its 200 day moving average price is $740.94. argenex SE has a 52 week low of $510.05 and a 52 week high of $934.62.

argenex (NASDAQ:ARGX) last posted its earnings results on Thursday, October 30th. The company reported $4.40 EPS for the quarter, topping the consensus estimate of $4.37 by $0.03. The company had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.07 billion. argenex had a net margin of 41.58% and a return on equity of 29.78%. As a group, sell-side analysts forecast that argenex SE will post 3.13 earnings per share for the current fiscal year.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.